The Second Lane

A new lane just opened in severe alopecia. For a decade the field has run through the same three JAK-inhibitor pills — Olumiant, Litfulo, Leqselvi — and the only way patients and doctors could move was up the dose or over to a different pill in the same class. Q32 Bio's bempikibart, an antibody aimed at IL-7R instead of JAK kinases, just produced a 30.3% SALT-20 response in 33 patients at 36 weeks, per Fierce Biotech's reporting on the company's July 13 release. That is a modest absolute number. The market read it differently: shares opened about 63% above Friday's close and touched $22.50 by mid-morning — a gap-up that does not match the data line by line.

Call it the second-lane trade: a small-N, single-arm readout re-rated like a paradigm shift because the mechanism is genuinely new. The durability story — company-sourced "early signs" of regrowth holding off-drug, per Q32 Bio's July 13 release — hints that the JAK class's biggest liability, rapid relapse on stop, might not be intrinsic to the disease. The honest read: n=33, no control arm, no head-to-head, and "durability" is a single company's framing rather than a demonstrated result. What the 60% move really priced is the optionality on a different pathway. The H1 2027 registration program is where that optionality either compounds or collapses.